HUL posted an in-line performance, with revenue/EBITDA clocking growth of 35/43% YoY (HSIE 34/46%). Ex-GSK, revenue grew by 21% YoY (6% 2-year CAGR) with UVG of 16% YoY (4.5% 2-year CAGR). The company saw demand recovery in in discretionary and OOH categories and revenue pressure eased out. Health, Hygiene and Nutrition (80% mix) continued to deliver strong double-digit growth, supported by new launches and price hikes. Market share gains (>80% portfolio gained share) continued, well supported by strong rural and sustained momentum in e-comm (most profitable channel for HUL). Varun Lohchab, Institutional Research Analyst, HDFC Securities, Naveen Trivedi, Institutional Research Analyst, HDFC Securities